Heavy Light Chain in Chronic Lymphocytic Leukemia
Heavy Light Chain in Chronic Lymphocytic Leukemia
Recently, a novel assay for detecting heavy/light chain (HLC) ratios has been reported which
 enables improvement in paraprotein detection and monitoring in multiple myeloma and other
 plasma-cell dyscrasias.

 The prognostic and biological role of the HLC assay has as yet not been studied in CLL.

 Aims of the proposed study:

 1. To quantify and analyze the prognostic significance of HLC ratios in the serum of CLL
 patients. (In addition to FLC)

 2. To study the different patterns of Immunoglobulin's subclass antibodies in the serum of
 patients with CLL and compare them to those of to healthy volunteers.

 3. To perform a sub-analysis in patients with CLL who have autoimmune phenomenon (AIHA and
 ITP)
Analysis of immunoglobulin heavy/light chain pairs In chronic lymphocytic leukemia

 Introduction and Background:

 Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in the western world.
 Median age at diagnosis is 72 years, and the male to female ratio is 2:1. The disease is
 characterized by an accumulation of monoclonal mature B-cells which co-express the T-cell
 antigen CD5, B-cell surface antigens CD19, CD20, and CD23(1) and either kappa or lambda
 immunoglobulin light chains restriction (2). Diagnosis is established based on the IWCLL
 criteria published by Hallek at al in 2008. (1).

 CLL may have a heterogeneous clinical course with a wide spectrum of manifestations ranging
 from long lived asymptomatic patients who never require treatment to those with a more rapid
 clinical course and symptomatic progression. One of the remaining important challenges in CLL
 is to stratify patients into different prognostic categories, so as to plan appropriate
 targeted therapy when necessary . The most important prognostic factor in CLL relates to the
 presence of typical genomic aberrations in the leukemic cell (3). Other essential prognostic
 parameters include: CD38 expression, the presence of ZAP-70, immunoglobulin heavy chain
 mutational status, and beta 2 microglobulin (B2MG) levels. (1).

 Patients with CLL, have a 10 % risk of developing autoimmune complications mostly auto-immune
 hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) (4-6). The pathogenesis for these
 autoimmune cytopenias is linked to the production of polyclonal immunoglobulin G (IgG)
 antibodies (less frequently IgM) directed against a variety of red blood cell or platelet
 antigens. (4-6).

 The use of serum free light chain (FLC) levels as an important prognostic tool in different
 plasma cell dyscrasias is already well established (75) while the prognostic significance of
 FLC in CLL has only been reported more recently by few publications (8-10). Furthermore, Tsai
 et al, have also described that serum FLC abnormalities may precede diagnosis in 38 % of
 patients with CLL (11).

 Recently, a novel assay for detecting heavy/light chain (HLC) ratios has been reported which
 enables improvement in paraprotein detection and monitoring in multiple myeloma and other
 plasma-cell dyscrasias. (12-13).

 The prognostic and biological role of the HLC assay has as yet not been studied in CLL.

 Aims of the proposed study:

 1. To quantify and analyze the prognostic significance of HLC ratios in the serum of CLL
 patients. (In addition to FLC)

 2. To study the different patterns of Immunoglobulin's subclass antibodies in the serum of
 patients with CLL and compare them to those of to healthy volunteers.

 3. To perform a sub-analysis in patients with CLL who have autoimmune phenomenon (AIHA and
 ITP)

 Materials and methods:

 The study will be performed in collaboration with the Israeli CLL Study Group.

 All patients included will have complete clinical database available and medical records
 summarized.

 Baseline laboratory parameters to be examined will include: complete blood count, Coombs
 test, serum B2MG and LDH, Immunoglobulin levels,, flow-cytometry including CD38 expression
 and ZAP70 and urine Bence Jones protein.

 Frozen serum samples from CLL patients will be analyzed for levels of:

 -  Free light chain: kappa/lambda, ratio of K/L and total sum of K+L.

 -  IgG1, IgG2, IgG3, IgG4.

 -  Isoforms of heavy/light chain of IgG kappa, IgG lambda, IgA kappa, IgA lambda, IgM
 kappa, IgM lambda

 References:

 1. Michael Hallek, Bruce D. Cheson, Daniel Catovsky, et al. Guidelines for the diagnosis
 and treatment of chronic lymphocytic leukemia: a report from the International Workshop
 on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group
 1996 guidelines. Blood. Jun 15, 2008; 111(12): 5446-5456.

 2. Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia
 scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin
 Pathol.1997;108:378-382.

 3. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic
 lymphocytic leukemia. N Engl J Med. 2000 Dec 28; 343(26):1910-6.

 4. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukemia. J Clin
 Pathol 1986;39;713-16

 5. Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best
 Pract Res Clin Haematol. 2010 Mar;23(1):47-59.

 6. Visco C, Barcellini W, Maura F, Neri A, Cortelezzi A, Rodeghiero F. Autoimmune
 cytopenias in chronic lymphocytic leukemia. Am J Hematol. 2014 Jun 10

 7. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines
 for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia.
 2009 Feb;23(2):215-24.

 8. Maurer MJ, Cerhan JR, Katzmann JA, et al. Monoclonal and polyclonal serum free light
 chains and clinical outcome in chronic lymphocytic leukemia. Blood. 2011 Sep
 8;118(10):2821-6

 9. Morabito F, De Filippi R, Laurenti L, et al. The cumulative amount of serum-free light
 chain is a strong prognosticator in chronic lymphocytic leukemia. Blood. 2011 Dec
 8;118(24):6353-61.

 10. Sarris K, Maltezas D, Koulieris E, et al. Prognostic significance of serum free light
 chains in chronic lymphocytic leukemia. Adv Hematol. 2013;2013:359071

 11. Tsai HT, Caporaso NE, Kyle RA, et al. Evidence of serum immunoglobulin abnormalities up
 to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study.
 Blood. 2009 Dec 3;114(24):4928-32

 12. Ludwig H, Milosavljevic D, Zojer N, et al. Immunoglobulin heavy/light chain ratios
 improve paraprotein detection and monitoring, identify residual disease and correlate
 with survival in multiple myeloma patients. Leukemia. 2013 Apr;27(4):996.

 13. Katzmann JA, Clark R, Kyle RA, et al. Suppression of uninvolved immunoglobulins defined
 by heavy/light chain pair suppression is a risk factor for progression of MGUS.
 Leukemia. 2013 Jan;27(1):208-12.
Inclusion Criteria:

 New diagnosed patients with CLL (untreated)

 Exclusion Criteria:

 Not treated with immunoglobulin Not treated with steroids